Related Experiment Video
Updated: May 1, 2026

Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis
Published on: June 3, 2016
Fibroblast growth factor 21: a promising therapeutic target in obesity-related diseases
1Department of Medicine, University of Hong Kong, Pokfulam, Hong Kong.
Abstract:
Fibroblast growth factor 21 (FGF21) is a peptide hormone secreted by the liver, adipocytes, pancreas and skeletal muscle. It acts locally but is also a circulating hormone. Administration of FGF21 in animals and humans results in a decrease in body weight, blood triglycerides and LDL-cholesterol, with improvement in insulin sensitivity. FGF21 is known to play an important role during fasting and starvation by stimulating gluconeogenesis in the liver and inducing lipolysis in white adipose tissues. FGF21 expression is mediated by the peroxisome proliferator-activated receptor-α, while its biological actions are mediated through binding to a complex formed by its receptors and an essential coreceptor, β-Klotho. Serum FGF21 levels are paradoxically elevated in obesity, suggesting a decreased responsiveness. Recent data showed that serum FGF21 level is elevated in hypertension, atherosclerosis and coronary artery disease, raising the possibility that FGF21 plays a role in the pathophysiology of these diseases.
Insights
Fibroblast growth factor 21 (FGF21) is a hormone that regulates metabolism and may improve insulin sensitivity. Elevated FGF21 levels in obesity and cardiovascular disease suggest altered responsiveness.
Area of Science:
- Endocrinology
- Metabolic research
Background:
- Fibroblast growth factor 21 (FGF21) is a key metabolic regulator.
- It influences glucose and lipid metabolism, particularly during fasting.
Purpose of the Study:
- To explore the physiological roles of FGF21.
- To investigate the link between FGF21 and metabolic/cardiovascular diseases.
Main Methods:
- Review of existing literature on FGF21.
- Analysis of FGF21's role in metabolic regulation and disease pathophysiology.
Main Results:
- FGF21 administration improves body weight, lipid profiles, and insulin sensitivity.
- FGF21 is implicated in fasting adaptation, stimulating hepatic gluconeogenesis and adipose lipolysis.
- Serum FGF21 is elevated in obesity, hypertension, atherosclerosis, and coronary artery disease, indicating potential resistance.
Conclusions:
- FGF21 is a crucial hormone in metabolic homeostasis.
- Its dysregulation and potential resistance in obesity and cardiovascular diseases warrant further investigation.
Related Concept Videos
Obesity
Introduction to Fibroblasts
TGF - β Signaling Pathway

